Zhejiang Ausun Pharmaceutical Co., Ltd. (SHA:603229)

SHA:603229 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	750.9	795.07	814.85	764.23	568.89	405.1
Other Revenue	0.22	0.22	1.92	0.32	0.81	4.15
Revenue	751.12	795.29	816.77	764.55	569.7	409.25
Revenue Growth (YoY)	-10.07%	-2.63%	6.83%	34.20%	39.21%	32.91%
Cost of Revenue	361.36	373.39	372.41	372.58	261.29	182.58
Gross Profit	389.76	421.9	444.36	391.96	308.41	226.67
Selling, General & Admin	116.84	123.21	118.41	114.55	81.25	63.71
Research & Development	118.02	100.42	78.06	67.07	68.82	50.77
Other Operating Expenses	15.53	6.54	3.32	1.97	4.64	4.05
Operating Expenses	248.39	236.19	199.81	186.76	156.21	117.78
Operating Income	141.38	185.71	244.54	205.2	152.2	108.89
Interest Expense	-7.74	-7.76	-7.99	-6.11	-1.47	-1.38
Interest & Investment Income	47.71	43.08	35.75	9.6	5.78	8.23
Currency Exchange Gain (Loss)	11.4	11.4	11.37	40.58	-9.67	-21.72
Other Non Operating Income (Expenses)	1.94	-1.5	-0.6	-0.44	-0.44	-0.39
EBT Excluding Unusual Items	194.68	230.92	283.07	248.84	146.41	93.63
Gain (Loss) on Sale of Investments	5.3	5.5	-4.49	4.95	11.66	-5.23
Gain (Loss) on Sale of Assets	-	-	-	-	-0.52	-0.52
Asset Writedown	-0.19	-0.15	-0.37	-1.58	-	-
Other Unusual Items	12.47	3.93	12.55	3.66	1.84	7.62
Pretax Income	212.27	240.2	290.76	255.86	159.39	95.5
Income Tax Expense	27.43	33.41	36.86	20.48	13.46	8.66
Net Income	184.84	206.79	253.9	235.38	145.93	86.84
Net Income to Common	184.84	206.79	253.9	235.38	145.93	86.84
Net Income Growth	-28.23%	-18.55%	7.87%	61.29%	68.05%	54.00%
Shares Outstanding (Basic)	835	827	819	804	794	745
Shares Outstanding (Diluted)	835	827	819	804	794	745
Shares Change (YoY)	3.53%	0.99%	1.92%	1.16%	6.67%	0.25%
EPS (Basic)	0.22	0.25	0.31	0.29	0.18	0.12
EPS (Diluted)	0.22	0.25	0.31	0.29	0.18	0.12
EPS Growth	-30.68%	-19.36%	5.84%	59.45%	57.55%	53.62%
Free Cash Flow	143.8	66.62	58.38	-151.35	-136.95	45.52
Free Cash Flow Per Share	0.17	0.08	0.07	-0.19	-0.17	0.06
Dividend Per Share	0.100	0.100	0.092	0.057	0.037	0.023
Dividend Growth	8.58%	8.58%	61.30%	53.91%	62.72%	39.88%
Gross Margin	51.89%	53.05%	54.40%	51.27%	54.14%	55.39%
Operating Margin	18.82%	23.35%	29.94%	26.84%	26.72%	26.61%
Profit Margin	24.61%	26.00%	31.09%	30.79%	25.61%	21.22%
Free Cash Flow Margin	19.14%	8.38%	7.15%	-19.80%	-24.04%	11.12%
EBITDA	220.36	248.24	285.14	239.68	182.22	134.32
EBITDA Margin	29.34%	31.21%	34.91%	31.35%	31.99%	32.82%
D&A For EBITDA	78.99	62.53	40.59	34.48	30.02	25.43
EBIT	141.38	185.71	244.54	205.2	152.2	108.89
EBIT Margin	18.82%	23.35%	29.94%	26.84%	26.71%	26.61%
Effective Tax Rate	12.92%	13.91%	12.68%	8.01%	8.45%	9.07%
Revenue as Reported	751.12	795.29	816.77	764.55	569.7	409.25

Source: S&P Global Market Intelligence. Standard template. Financial Sources.